Biohaven Pharmaceutical said on May 23 the company’s experimental drug for patients with spinocerebellar ataxia, a genetic disease that affects the nervous system, failed to meet the main goal of a late-stage study.
Shares of Biohaven Pharmaceutical Holding Company Ltd. fell 16 percent after the company’s treatment for anxiety disorder failed to meet the main goal in a late-stage study.
